Purple Biotech Q2 FY26 net income swings to USD 400,000; operating loss widens to USD 1.3 million
Reuters2026/08/07 11:04- Purple Biotech posted IFRS net income of USD 0.4 million for Q2 2026, swinging from a net loss of USD 1.1 million a year earlier.
- IFRS operating loss widened to USD 1.3 million from USD 1.2 million, with R&D spending rising to USD 0.7 million from USD 0.6 million.
- IFRS finance income, net climbed to USD 1.7 million from USD 0.1 million on a higher non-cash gain from warrant revaluation.
- Cash and cash equivalents and short-term deposits totaled USD 6.1 million at June 30, 2026, seen funding operations through mid-2027.
- IM1240 tri-specific antibody is aimed at entering clinical studies in 2027; management said it is pursuing a strategic collaboration and financing alternatives.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Securitize to Help Develop Dubai’s Regulated Tokenized Asset Market
Audley Travel to open concessions in nine John Lewis stores from November 2026
Tessin Nordic Holding announces extraordinary shareholder meeting
Will a 10-year US Treasury yield rising to 5.5% "attack" US stocks? Societe Generale warns: this could be the valuation tipping point.
Bokobza, Global Head of Asset Allocation at Société Générale, pointed out that if the 10-year U.S. Treasury yield reaches 5.5%, corporate profit growth will not be sufficient to offset the impact of rising rates on valuations, and the stock market will face substantial pressure. However, he believes that the upcoming rate hikes by the Federal Reserve and the European Central Bank will be relatively limited and will not disrupt the current economic cycle.
Crypto prices
More
